AR016754A1 - Prediccion de enfermedad inflamatoria - Google Patents
Prediccion de enfermedad inflamatoriaInfo
- Publication number
- AR016754A1 AR016754A1 ARP980102477A ARP980102477A AR016754A1 AR 016754 A1 AR016754 A1 AR 016754A1 AR P980102477 A ARP980102477 A AR P980102477A AR P980102477 A ARP980102477 A AR P980102477A AR 016754 A1 AR016754 A1 AR 016754A1
- Authority
- AR
- Argentina
- Prior art keywords
- disease
- aplotype
- patient
- detection
- methods
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
- Y10T436/143333—Saccharide [e.g., DNA, etc.]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Physics & Mathematics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Physiology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Son revelados los métodos, ensayos y kits para la deteccion de la susceptibilidad de un paciente a desordenes inflamatorios tales como enfermedades arteriacoronarias (coronatiopatías),osteosporosis,nefropatía en diabetes mellitus, alopecía areata,el mal de Graves, lupus eritematoso sistémico, liquen esclerotico,colitis ulcerativa, retinopatía diabética, enfermedad piriodontal, artritis cronica juvenil, particularmente iridociclitis cronica, psoriasis, diabetesinsulinodependiente y otrasenferme dades con un componente genético IL-1. Los métodos están caracterizados por la obtencion de una muestra biologica de unpaciente y determinar la presencia o ausencia de un particular aplotipo del grupo IL-1, que está asociado con un desordeninflamato rio. La deteccion de por lomenos uno de los alelos en el aplotipo, indica susceptibilidad al desorden inflamatorio.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9711040.7A GB9711040D0 (en) | 1997-05-29 | 1997-05-29 | Prediction of inflammatory disease |
Publications (1)
Publication Number | Publication Date |
---|---|
AR016754A1 true AR016754A1 (es) | 2001-08-01 |
Family
ID=10813199
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP980102477A AR016754A1 (es) | 1997-05-29 | 1998-05-28 | Prediccion de enfermedad inflamatoria |
Country Status (19)
Country | Link |
---|---|
US (4) | US6268142B1 (es) |
EP (1) | EP0983385B1 (es) |
JP (1) | JP2002500513A (es) |
CN (1) | CN1177059C (es) |
AR (1) | AR016754A1 (es) |
AT (1) | ATE462800T1 (es) |
AU (1) | AU755107B2 (es) |
BR (1) | BR9809183A (es) |
CA (1) | CA2291731A1 (es) |
DE (1) | DE69841588D1 (es) |
EA (1) | EA199901097A1 (es) |
ES (1) | ES2342992T3 (es) |
GB (1) | GB9711040D0 (es) |
IL (1) | IL133128A0 (es) |
NO (1) | NO995803L (es) |
PL (1) | PL337080A1 (es) |
TW (1) | TWI236502B (es) |
WO (1) | WO1998054359A1 (es) |
ZA (1) | ZA984490B (es) |
Families Citing this family (93)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6524795B1 (en) * | 1997-03-10 | 2003-02-25 | Interleukin Genetics, Inc. | Diagnostics for cardiovascular disorders |
US7820383B2 (en) | 1997-03-10 | 2010-10-26 | Interleukin Genetics, Inc. | Method for diagnosing myocardial infarction |
US6720141B1 (en) * | 1999-11-01 | 2004-04-13 | Interleukin Genetics, Inc. | Diagnostics and therapeutics for restenosis |
US20050282198A1 (en) * | 1997-05-29 | 2005-12-22 | Interleukin Genetics, Inc. | Diagnostics and therapeutics for diseases associated with an IL-1 inflammatory haplotype |
GB9723553D0 (en) * | 1997-11-07 | 1998-01-07 | Duff Gordon W | Prediction of the risk of chronic obstructive airway disease |
AU760856B2 (en) * | 1997-05-29 | 2003-05-22 | Interleukin Genetics, Inc. | Diagnostics and therapeutics for chronic obstructive airway disease |
GB9711040D0 (en) | 1997-05-29 | 1997-07-23 | Duff Gordon W | Prediction of inflammatory disease |
US6746839B1 (en) | 1998-01-12 | 2004-06-08 | Interleukin Genetics, Inc. | Diagnostics and therapeutics for an obstructive airway disease |
US20050032077A1 (en) * | 1998-03-10 | 2005-02-10 | Duff Gordon W. | Detecting genetic predisposition to sight-threatening diabetic retinopathy |
GB2336431B (en) * | 1998-04-17 | 2003-06-25 | Johnson & Johnson Medical Ltd | Method of analysis of chronic wounds |
US6733967B1 (en) | 1998-04-21 | 2004-05-11 | Interleukin Genetics, Inc. | Fetal testing for prediction of low birth weight |
IL139131A0 (en) * | 1998-04-21 | 2001-11-25 | Interleukin Genetics Inc | Fetal testing for prediction of low birth weight |
US6251598B1 (en) * | 1998-10-30 | 2001-06-26 | Interleukin Genetics, Inc. | Methods for diagnosing sepsis |
IL144492A0 (en) * | 1999-02-10 | 2002-05-23 | Interleukin Genetics Inc | Therapeutics and diagnostics based on an il-1b mutation |
CA2367294A1 (en) * | 1999-04-02 | 2000-10-12 | Interleukin Genetics, Inc. | Prediction of risk of interstitial lung disease |
WO2001000880A2 (en) * | 1999-06-30 | 2001-01-04 | Interleukin Genetics, Inc. | Diagnostics and therapeutics for diseases associated with an il-1 inflammatory haplotype |
US20090023147A1 (en) * | 1999-08-30 | 2009-01-22 | Kenneth Kornman | Diagnostics and therapeutics for osteoporosis |
ATE318328T1 (de) * | 1999-08-30 | 2006-03-15 | Interleukin Genetics Inc | Diagnostika und therapeutika für osteoporose |
US20030054002A1 (en) * | 2000-05-17 | 2003-03-20 | Board Of Regents, The University Of Texas System | Isolation of genes within SLE-1B that mediate a break in immune tolerance |
WO2002000933A2 (en) * | 2000-06-23 | 2002-01-03 | Interleukin Genetics, Inc. | Screening assays for identifying modulators of the inflammatory or immune responses |
US20020168639A1 (en) * | 2000-09-22 | 2002-11-14 | Muraca Patrick J. | Profile array substrates |
JP2002345500A (ja) * | 2000-12-22 | 2002-12-03 | Pfizer Prod Inc | 炎症性障害を発展させる増加したリスクを検出するための方法および試薬 |
NZ545283A (en) * | 2001-06-05 | 2008-01-31 | Auckland Uniservices Ltd | Methods and compositions for determining a subject's predisposition to developing impaired lung function |
EP1409737A4 (en) * | 2001-06-15 | 2005-10-12 | Interleukin Genetics Inc | METHODS OF DETECTING AND TREATING EARLY APPEARANCE OF CONDITIONS RELATED TO AGING |
US20050202421A1 (en) * | 2001-10-31 | 2005-09-15 | Raphael Hirsch | Method for diagnosis and treatment of rheumatoid arthritis |
US20080311581A1 (en) * | 2001-11-19 | 2008-12-18 | David Wyllie | Functional polymorphisms of the interleukin-1 locus affecting transcription and susceptibility to inflammatory and infectious diseases |
KR101019131B1 (ko) | 2001-11-19 | 2011-03-07 | 인터레우킨 제네틱스, 인코포레이티드 | 염증성 질환 및 감염성 질환에 대한 감수성 및 전사에영향을 미치는 인터루킨-1 좌의 기능적 다형성 |
US20070264645A1 (en) * | 2002-01-25 | 2007-11-15 | Kenneth Kornman | IL-1 gene cluster and associated inflammatory polymorphisms and haplotypes |
TWI346700B (en) * | 2002-01-25 | 2011-08-11 | Interleukin Genetics Inc | The il-1 gene cluster and associated inflammatory polymorphisms and haplotypes |
US20040048287A1 (en) * | 2002-05-20 | 2004-03-11 | Smith Lloyd M. | Label-free detection of single nucleotide polymorphisms using surface plasmon resonance imaging |
US9388459B2 (en) * | 2002-06-17 | 2016-07-12 | Affymetrix, Inc. | Methods for genotyping |
KR20040001552A (ko) * | 2002-06-28 | 2004-01-07 | 주식회사 인투젠 | 디엔에이 결합 단백질 비에 대한 자가항체에 결합할 수있는 단백질을 유효 성분으로 함유하는 전신성 경화증진단용 조성물, 이를 이용한 상기 자가항체의 검출 방법및 전신성 경화증 진단 방법 |
US20040229228A1 (en) * | 2002-07-25 | 2004-11-18 | Northwestern University | Il-1 genotype in early kidney allograft rejection |
US7732134B2 (en) * | 2002-09-30 | 2010-06-08 | Novartis Ag | Methods to predict cholesterol elevation during immunosuppressant therapy |
CN1711361A (zh) * | 2002-10-15 | 2005-12-21 | 诺瓦提斯公司 | 预测药物治疗副效应水肿的方法 |
US10229244B2 (en) * | 2002-11-11 | 2019-03-12 | Affymetrix, Inc. | Methods for identifying DNA copy number changes using hidden markov model based estimations |
US7424368B2 (en) * | 2002-11-11 | 2008-09-09 | Affymetix, Inc. | Methods for identifying DNA copy number changes |
US7822555B2 (en) | 2002-11-11 | 2010-10-26 | Affymetrix, Inc. | Methods for identifying DNA copy number changes |
WO2005013809A2 (en) | 2003-08-08 | 2005-02-17 | Interleukin Genetics, Inc. | Diagnostic and therapeutics for osteoporosis |
ES2523147T3 (es) * | 2004-02-26 | 2014-11-21 | Baylor Research Institute | Composiciones y métodos para el tratamiento sistémico de la artritis |
US7309589B2 (en) | 2004-08-20 | 2007-12-18 | Vironix Llc | Sensitive detection of bacteria by improved nested polymerase chain reaction targeting the 16S ribosomal RNA gene and identification of bacterial species by amplicon sequencing |
WO2006097388A2 (en) * | 2005-02-08 | 2006-09-21 | Innogenetics N.V. | Nucleic acid variants in the c1qr1 gene associated with altered innate immunity. |
EP1896607A4 (en) * | 2005-05-10 | 2009-12-16 | Synergenz Bioscience Ltd | METHOD AND COMPOSITIONS FOR THE ASSESSMENT OF LUNG FUNCTION AND RESPIRATORY DISEASE |
WO2006123955A2 (en) * | 2005-05-19 | 2006-11-23 | Synergenz Bioscience Limited | Methods for the assesssment of risk of developing lung cancer using analysis of genetic polymorphisms |
CA2608158A1 (en) * | 2005-05-19 | 2006-11-23 | Synergenz Bioscience Limited | Methods and compositions for assessment of pulmonary function and disorders |
US7933722B2 (en) * | 2005-05-20 | 2011-04-26 | Synergenz Bioscience Limited | Methods of analysis of polymorphisms and uses thereof |
US8202546B2 (en) | 2005-08-04 | 2012-06-19 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for use under physiologically stressful conditions |
US8263137B2 (en) * | 2005-08-04 | 2012-09-11 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for women |
US7998500B2 (en) * | 2005-08-04 | 2011-08-16 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for women |
US7901710B2 (en) * | 2005-08-04 | 2011-03-08 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for use under physiologically stressful conditions |
WO2007023148A2 (en) * | 2005-08-22 | 2007-03-01 | Innogenetics N.V. | Nucleic acid variants in the lbp gene associated with altered innate immunity |
WO2007022590A1 (en) * | 2005-08-24 | 2007-03-01 | Genetic Technologies Limited | Identification of ancestral haplotypes and uses thereof |
WO2007050794A2 (en) | 2005-10-25 | 2007-05-03 | Interleuken Genetics, Inc. | The il-1 gene cluster and associated inflammatory polymorphisms and haplotypes |
US11306351B2 (en) | 2005-12-21 | 2022-04-19 | Affymetrix, Inc. | Methods for genotyping |
US8338109B2 (en) | 2006-11-02 | 2012-12-25 | Mayo Foundation For Medical Education And Research | Predicting cancer outcome |
WO2008060627A2 (en) * | 2006-11-15 | 2008-05-22 | Interleukin Genetics, Inc. | The il-1 gene cluster, insulin resistance and coronary artery disease associated polymorphisms and haplotypes and methods of using same |
CN101230386B (zh) * | 2007-04-28 | 2011-09-14 | 廖凌虹 | 检测CYP2E1基因的单核苷酸多态性位点rs2480256的引物在制造用于评估系统性红斑狼疮易感性的试剂盒的用途 |
US8200440B2 (en) | 2007-05-18 | 2012-06-12 | Affymetrix, Inc. | System, method, and computer software product for genotype determination using probe array data |
US20080293589A1 (en) * | 2007-05-24 | 2008-11-27 | Affymetrix, Inc. | Multiplex locus specific amplification |
WO2009135218A2 (en) * | 2008-05-02 | 2009-11-05 | Interleukin Genetics, Inc. | Detecting genetic predisposition to osteoarthritis associated conditions |
EP2291553A4 (en) | 2008-05-28 | 2011-12-14 | Genomedx Biosciences Inc | SYSTEMS AND METHODS FOR THE EXPRESSION-BASED DISTINCTION OF DIFFERENT CLINICAL ILLICIT STADIAS IN PROSTATE CANCER |
US10407731B2 (en) | 2008-05-30 | 2019-09-10 | Mayo Foundation For Medical Education And Research | Biomarker panels for predicting prostate cancer outcomes |
US10236078B2 (en) | 2008-11-17 | 2019-03-19 | Veracyte, Inc. | Methods for processing or analyzing a sample of thyroid tissue |
US9495515B1 (en) | 2009-12-09 | 2016-11-15 | Veracyte, Inc. | Algorithms for disease diagnostics |
US9074258B2 (en) | 2009-03-04 | 2015-07-07 | Genomedx Biosciences Inc. | Compositions and methods for classifying thyroid nodule disease |
CN103223177B (zh) * | 2009-05-06 | 2016-08-10 | 库尔纳公司 | 通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病 |
JP6078339B2 (ja) | 2009-05-07 | 2017-02-08 | ベラサイト インコーポレイテッド | 甲状腺状態の診断のための方法および組成物 |
US10446272B2 (en) | 2009-12-09 | 2019-10-15 | Veracyte, Inc. | Methods and compositions for classification of samples |
ES2680545T3 (es) * | 2010-02-26 | 2018-09-10 | Qiagen Gmbh | Proceso de aislamiento y/o purificación paralela de ARN y ADN |
NZ612799A (en) | 2010-12-09 | 2015-04-24 | Interleukin Genetics Inc | Improved method and kit for determining severity and progression of periodontal disease |
CA2858581A1 (en) | 2011-12-13 | 2013-06-20 | Genomedx Biosciences, Inc. | Cancer diagnostics using non-coding transcripts |
CA2881627A1 (en) | 2012-08-16 | 2014-02-20 | Genomedx Biosciences Inc. | Cancer diagnostics using biomarkers |
EP3626308A1 (en) | 2013-03-14 | 2020-03-25 | Veracyte, Inc. | Methods for evaluating copd status |
US11976329B2 (en) | 2013-03-15 | 2024-05-07 | Veracyte, Inc. | Methods and systems for detecting usual interstitial pneumonia |
CN103397022A (zh) * | 2013-07-17 | 2013-11-20 | 上海交通大学医学院附属瑞金医院 | 与Graves病或Graves眼病相关的核苷酸多态性标记及其应用 |
WO2016073768A1 (en) | 2014-11-05 | 2016-05-12 | Veracyte, Inc. | Systems and methods of diagnosing idiopathic pulmonary fibrosis on transbronchial biopsies using machine learning and high dimensional transcriptional data |
WO2017123696A1 (en) | 2016-01-12 | 2017-07-20 | Interleukin Genetics, Inc. | Methods for predicting response to treatment |
EP3504348B1 (en) | 2016-08-24 | 2022-12-14 | Decipher Biosciences, Inc. | Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy |
US10337070B2 (en) | 2017-01-12 | 2019-07-02 | Cardioforecast Ltd. | Methods and kits for treating cardiovascular disease |
US11208697B2 (en) | 2017-01-20 | 2021-12-28 | Decipher Biosciences, Inc. | Molecular subtyping, prognosis, and treatment of bladder cancer |
WO2018165600A1 (en) | 2017-03-09 | 2018-09-13 | Genomedx Biosciences, Inc. | Subtyping prostate cancer to predict response to hormone therapy |
AU2018266733A1 (en) | 2017-05-12 | 2020-01-16 | Veracyte, Inc. | Genetic signatures to predict prostate cancer metastasis and identify tumor aggressiveness |
US11217329B1 (en) | 2017-06-23 | 2022-01-04 | Veracyte, Inc. | Methods and systems for determining biological sample integrity |
DE102018104133A1 (de) * | 2018-02-23 | 2019-08-29 | Klinikum der Universität München, Anstalt des öffentlichen Rechts | Biomarker zur Feststellung einer möglichen Unverträglichkeit gegenüber Metallimplantaten |
US20210140974A1 (en) * | 2018-04-12 | 2021-05-13 | Mayo Foundation For Medical Education And Research | Methods for guiding therapy decisions in seizure disorders |
CN109295211A (zh) * | 2018-10-30 | 2019-02-01 | 深圳市万众基因转化医学研究院 | 一种人类斑秃相关基因突变筛查的组合引物及其应用 |
WO2020150633A1 (en) | 2019-01-18 | 2020-07-23 | Orthobio Therapeutics, Inc. | Gene editing to improve joint function |
WO2020215051A1 (en) * | 2019-04-19 | 2020-10-22 | Rpi Consulting Llc | Treatments for pregnancy-related conditions |
EP3980561A1 (en) | 2019-06-06 | 2022-04-13 | Sitokine Limited | Compositions and methods for treating lung, colorectal and breast cancer |
WO2021028469A1 (en) | 2019-08-12 | 2021-02-18 | Sitokine Limited | Compositions and methods for treating cytokine release syndrome and neurotoxicity |
WO2021205013A1 (en) | 2020-04-09 | 2021-10-14 | Sitokine Limited | Compositions and methods for treating covid-19 |
CA3186119A1 (en) * | 2020-07-16 | 2022-01-20 | Orthobio Therapeutics, Inc. | Gene editing to improve joint function |
WO2023283021A1 (en) * | 2021-07-08 | 2023-01-12 | Martin Levine | Devices, kits, and methods for determining increased susceptibility to and treatment and prevention of periodontitis, alzheimer's disease, and other conditions |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3587605T2 (de) * | 1984-12-25 | 1994-03-17 | Dainippon Pharmaceutical Co | Interleukin-1 und dessen Derivat. |
US5582979A (en) * | 1989-04-21 | 1996-12-10 | Marshfield Clinic | Length polymorphisms in (dC-dA)n.(dG-dT)n sequences and method of using the same |
US5780587A (en) * | 1990-08-24 | 1998-07-14 | President And Fellows Of Harvard College | Compounds and methods for inhibiting β-protein filament formation and neurotoxicity |
US5681940A (en) * | 1994-11-02 | 1997-10-28 | Icn Pharmaceuticals | Sugar modified nucleosides and oligonucleotides |
US5993817A (en) * | 1995-01-23 | 1999-11-30 | Xenotech | Method to ameliorate osteolysis and metastasis |
US5686246A (en) | 1995-08-03 | 1997-11-11 | Kornman; Kenneth S. | Detecting genetic predisposition to periodontal disease |
US5942390A (en) | 1996-01-12 | 1999-08-24 | Cedars-Sinai Medical Center | Method of diagnosing predisposition for ulcerative colitis in Jewish population by detection of interleukin-1 receptor antagonist polymorphism |
US5698399A (en) * | 1996-04-05 | 1997-12-16 | Duff; Gordon W. | Detecting genetic predisposition for osteoporosis |
GB9610281D0 (en) * | 1996-05-16 | 1996-07-24 | Ralston Stuart H | Diagnostic method and apparatus |
GB9621129D0 (en) | 1996-10-10 | 1996-11-27 | Duff Gordon W | Detecting genetic predisposition to sight-threatening diabetic retinopathy |
US6210877B1 (en) * | 1997-03-10 | 2001-04-03 | Interleukin Genetics, Inc. | Prediction of coronary artery disease |
GB9706359D0 (en) | 1997-03-27 | 1997-05-14 | Gemini International Holdings | Polymorphisms of an il-1 receptor antagonist gene |
GB9711040D0 (en) | 1997-05-29 | 1997-07-23 | Duff Gordon W | Prediction of inflammatory disease |
GB9723553D0 (en) * | 1997-11-07 | 1998-01-07 | Duff Gordon W | Prediction of the risk of chronic obstructive airway disease |
US6746839B1 (en) * | 1998-01-12 | 2004-06-08 | Interleukin Genetics, Inc. | Diagnostics and therapeutics for an obstructive airway disease |
US6733967B1 (en) * | 1998-04-21 | 2004-05-11 | Interleukin Genetics, Inc. | Fetal testing for prediction of low birth weight |
US6251598B1 (en) * | 1998-10-30 | 2001-06-26 | Interleukin Genetics, Inc. | Methods for diagnosing sepsis |
EP1409737A4 (en) * | 2001-06-15 | 2005-10-12 | Interleukin Genetics Inc | METHODS OF DETECTING AND TREATING EARLY APPEARANCE OF CONDITIONS RELATED TO AGING |
KR101019131B1 (ko) * | 2001-11-19 | 2011-03-07 | 인터레우킨 제네틱스, 인코포레이티드 | 염증성 질환 및 감염성 질환에 대한 감수성 및 전사에영향을 미치는 인터루킨-1 좌의 기능적 다형성 |
-
1997
- 1997-05-29 GB GBGB9711040.7A patent/GB9711040D0/en active Pending
-
1998
- 1998-05-21 DE DE69841588T patent/DE69841588D1/de not_active Expired - Lifetime
- 1998-05-21 BR BR9809183-2A patent/BR9809183A/pt not_active Application Discontinuation
- 1998-05-21 IL IL13312898A patent/IL133128A0/xx unknown
- 1998-05-21 CA CA002291731A patent/CA2291731A1/en not_active Abandoned
- 1998-05-21 WO PCT/GB1998/001481 patent/WO1998054359A1/en active IP Right Grant
- 1998-05-21 CN CNB98807656XA patent/CN1177059C/zh not_active Expired - Lifetime
- 1998-05-21 PL PL98337080A patent/PL337080A1/xx unknown
- 1998-05-21 AU AU75398/98A patent/AU755107B2/en not_active Ceased
- 1998-05-21 ES ES98922938T patent/ES2342992T3/es not_active Expired - Lifetime
- 1998-05-21 EA EA199901097A patent/EA199901097A1/ru unknown
- 1998-05-21 EP EP98922938A patent/EP0983385B1/en not_active Expired - Lifetime
- 1998-05-21 JP JP50035899A patent/JP2002500513A/ja active Pending
- 1998-05-21 AT AT98922938T patent/ATE462800T1/de not_active IP Right Cessation
- 1998-05-26 ZA ZA984490A patent/ZA984490B/xx unknown
- 1998-05-28 AR ARP980102477A patent/AR016754A1/es unknown
- 1998-05-29 TW TW087108415A patent/TWI236502B/zh not_active IP Right Cessation
-
1999
- 1999-06-30 US US09/345,217 patent/US6268142B1/en not_active Expired - Lifetime
- 1999-11-26 NO NO995803A patent/NO995803L/no not_active Application Discontinuation
-
2001
- 2001-04-27 US US09/845,129 patent/US6706478B2/en not_active Expired - Lifetime
-
2004
- 2004-03-15 US US10/802,061 patent/US20040152124A1/en not_active Abandoned
-
2007
- 2007-10-02 US US11/866,073 patent/US20080187920A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU7539898A (en) | 1998-12-30 |
BR9809183A (pt) | 2000-08-01 |
NO995803D0 (no) | 1999-11-26 |
EA199901097A1 (ru) | 2000-06-26 |
US20040152124A1 (en) | 2004-08-05 |
US20020146700A1 (en) | 2002-10-10 |
AU755107B2 (en) | 2002-12-05 |
DE69841588D1 (de) | 2010-05-12 |
IL133128A0 (en) | 2001-03-19 |
US6706478B2 (en) | 2004-03-16 |
ATE462800T1 (de) | 2010-04-15 |
TWI236502B (en) | 2005-07-21 |
ES2342992T3 (es) | 2010-07-20 |
WO1998054359A1 (en) | 1998-12-03 |
ZA984490B (en) | 1998-12-02 |
EP0983385B1 (en) | 2010-03-31 |
PL337080A1 (en) | 2000-07-31 |
EP0983385A1 (en) | 2000-03-08 |
NO995803L (no) | 2000-01-18 |
GB9711040D0 (en) | 1997-07-23 |
CA2291731A1 (en) | 1998-12-03 |
US20080187920A1 (en) | 2008-08-07 |
US6268142B1 (en) | 2001-07-31 |
JP2002500513A (ja) | 2002-01-08 |
CN1278868A (zh) | 2001-01-03 |
CN1177059C (zh) | 2004-11-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR016754A1 (es) | Prediccion de enfermedad inflamatoria | |
Lang et al. | BDNF serum concentrations in healthy volunteers are associated with depression-related personality traits | |
Tohid et al. | Major depression and psoriasis: a psychodermatological phenomenon | |
Lin et al. | A comprehensive optogenetic pharmacology toolkit for in vivo control of GABAA receptors and synaptic inhibition | |
Autry et al. | Gender-specific impact of brain-derived neurotrophic factor signaling on stress-induced depression-like behavior | |
AR011943A1 (es) | Prediccion de enfermedades de la arteria coronaria | |
Moran et al. | Gene× environment interactions in schizophrenia: evidence from genetic mouse models | |
Jones et al. | Sex differences in the regulation of serotonergic transmission and behavior in 5-HT receptor knockout mice | |
Mo et al. | Restraint stress increases serotonin release in the central nucleus of the amygdala via activation of corticotropin-releasing factor receptors | |
McCaffery et al. | Allelic variation in the serotonin transporter gene-linked polymorphic region (5-HTTLPR) and cardiovascular reactivity in young adult male and female twins of European-American descent | |
Mellion et al. | Small‐fiber degeneration in alcohol‐related peripheral neuropathy | |
Morshedian et al. | Cambrian origin of the CYP27C1-mediated vitamin A1-to-A2 switch, a key mechanism of vertebrate sensory plasticity | |
Cole et al. | Effects of ethanol exposure on nervous system development in zebrafish | |
Reyes et al. | Stress-induced sensitization of cortical adrenergic receptors following a history of cannabinoid exposure | |
Pessah et al. | Immunologic and neurodevelopmental susceptibilities of autism | |
Zhao et al. | Behaviors related to psychiatric disorders and pain perception in C57BL/6J mice during different phases of estrous cycle | |
Spafford et al. | In vitro characterization of L-type calcium channels and their contribution to firing behavior in invertebrate respiratory neurons | |
Dohn et al. | The gain-of-function integrin β3 Pro33 variant alters the serotonin system in the mouse brain | |
Mousavi et al. | Comparative evaluation of adolescent repeated psychological or physical stress effects on adult cognitive performance, oxidative stress, and heart rate in female rats | |
Besson et al. | Alterations in alpha5* nicotinic acetylcholine receptors result in midbrain-and hippocampus-dependent behavioural and neural impairments | |
Huynh et al. | Chronic neurobehavioral impairments and decreased hippocampal expression of genes important for brain glucose utilization in a mouse model of mild TBI | |
Blizard | Situational determinants of open‐field behaviour in Mus musculus | |
Way et al. | Nonsynonymous HTR2C polymorphism predicts cortisol response to psychosocial stress II: Evidence from two samples | |
Zheng et al. | Reduction of prohibitin expression contributes to left ventricular hypertrophy via enhancement of mitochondrial reactive oxygen species formation in spontaneous hypertensive rats | |
Vache et al. | A potential genomic biomarker for the detection of polycyclic aromatic hydrocarbon pollutants: multidrug resistance gene 49 in Drosophila melanogaster |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |